JP2022500469A5 - - Google Patents
Info
- Publication number
- JP2022500469A5 JP2022500469A5 JP2021515027A JP2021515027A JP2022500469A5 JP 2022500469 A5 JP2022500469 A5 JP 2022500469A5 JP 2021515027 A JP2021515027 A JP 2021515027A JP 2021515027 A JP2021515027 A JP 2021515027A JP 2022500469 A5 JP2022500469 A5 JP 2022500469A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- cycloalkyl
- haloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732595P | 2018-09-18 | 2018-09-18 | |
| US62/732,595 | 2018-09-18 | ||
| PCT/US2019/051275 WO2020060916A1 (en) | 2018-09-18 | 2019-09-16 | Cycloheptyl acids as lpa antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500469A JP2022500469A (ja) | 2022-01-04 |
| JP2022500469A5 true JP2022500469A5 (enExample) | 2023-11-08 |
| JP7429224B2 JP7429224B2 (ja) | 2024-02-07 |
Family
ID=68073224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515027A Active JP7429224B2 (ja) | 2018-09-18 | 2019-09-16 | Ｌｐａアンタゴニストとしてのシクロヘプチル酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220041572A1 (enExample) |
| EP (1) | EP3852747B1 (enExample) |
| JP (1) | JP7429224B2 (enExample) |
| KR (1) | KR102800284B1 (enExample) |
| CN (1) | CN112702998A (enExample) |
| ES (1) | ES2948793T3 (enExample) |
| WO (1) | WO2020060916A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) * | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| WO2025051267A1 (zh) | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2026061483A1 (zh) * | 2024-09-19 | 2026-03-26 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| JP2015520202A (ja) | 2012-06-20 | 2015-07-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｐａｒ拮抗薬としてのｎ−アルキルトリアゾール化合物 |
| AR108838A1 (es) * | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP3853232B1 (en) | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
-
2019
- 2019-09-16 ES ES19779300T patent/ES2948793T3/es active Active
- 2019-09-16 WO PCT/US2019/051275 patent/WO2020060916A1/en not_active Ceased
- 2019-09-16 JP JP2021515027A patent/JP7429224B2/ja active Active
- 2019-09-16 US US17/276,178 patent/US20220041572A1/en not_active Abandoned
- 2019-09-16 KR KR1020217011086A patent/KR102800284B1/ko active Active
- 2019-09-16 EP EP19779300.3A patent/EP3852747B1/en active Active
- 2019-09-16 CN CN201980060422.9A patent/CN112702998A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500470A5 (enExample) | ||
| JP2022500469A5 (enExample) | ||
| JP2022500473A5 (enExample) | ||
| JP2021508686A5 (enExample) | ||
| JP2021507895A5 (enExample) | ||
| JP2021506878A5 (enExample) | ||
| JP2021507896A5 (enExample) | ||
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| JP2021507900A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| CN103443098B (zh) | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 | |
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP6534675B2 (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| JP2020528889A5 (enExample) | ||
| JP2023544476A5 (enExample) | ||
| JP6824954B2 (ja) | ｍＩＤＨ１阻害剤としての５−ヒドロキシアルキルベンズイミダゾール | |
| JP6824952B2 (ja) | ｍＩＤＨ１阻害剤としての２−アリール−および２−アリールアルキル−ベンズイミダゾール | |
| JP2011523945A5 (enExample) | ||
| JP2019530669A5 (enExample) | ||
| JP7683930B2 (ja) | セミカルバジド感受性アミンオキシダーゼ阻害剤の調製及びその応用 | |
| JP6830909B2 (ja) | ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール | |
| JP2008513498A5 (enExample) | ||
| JP6783756B2 (ja) | ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン | |
| JP2016535784A5 (enExample) | ||
| JP2017511794A5 (enExample) |